Celgene Corp (CELG)

113.62
NASDAQ : Health Care
Prev Close 113.62
Day Low/High 0.00 / 0.00
52 Wk Low/High 93.05 / 127.00
Avg Volume 5.05M
Exchange NASDAQ
Shares Outstanding 775.20M
Market Cap 89.11B
EPS 2.00
P/E Ratio 43.81
Div & Yield N.A. (N.A)

Latest News

Nasdaq Hits Records Even as Crude Selloff Sours Rest of Market

Nasdaq Hits Records Even as Crude Selloff Sours Rest of Market

A selloff in crude oil proves another roadblock in the Dow Jones Industrial Average's pursuit of 20,000.

Celgene Sees Much Higher Profits, but Wall Street Still Yawns

Celgene Sees Much Higher Profits, but Wall Street Still Yawns

Here's what the market chose to focus on instead.

Celgene Ups Revenue and Profit Projections for 2017, but Stock Falls

Celgene Ups Revenue and Profit Projections for 2017, but Stock Falls

Celgene executives have raised guidance for the year, but the stock retreated Monday.

Celgene Corporation Announces Preliminary 2016 Unaudited Results And 2017 Financial Guidance

Celgene Corporation Announces Preliminary 2016 Unaudited Results And 2017 Financial Guidance

Celgene Corporation (NASDAQ:CELG) today provided a business update as well as its preliminary 2016 unaudited results and financial guidance for 2017 at the 35 th Annual J.

Market Recon: Only the Tape Tells the Truth

Market Recon: Only the Tape Tells the Truth

It doesn't really matter where you think a stock should trade at.

Alphabet, Apple, Allergan: Doug Kass' Views

Alphabet, Apple, Allergan: Doug Kass' Views

Doug Kass shares his thoughts on the deepening of retail stocks' weakness and the Amazon Effect.

Here Are 6 Things to Watch Out for at J.P. Morgan's Healthcare Conference Next Week

Here Are 6 Things to Watch Out for at J.P. Morgan's Healthcare Conference Next Week

Next week the J.P. Morgan Healthcare Conference becomes the hottest spot in biotech and pharma.

Jim Cramer on the Problems With Buying Drug Stocks

Jim Cramer on the Problems With Buying Drug Stocks

Jim Cramer breaks down why it is so difficult to buy drug stocks right now.

Here's What to Look for at the J.P. Morgan Healthcare Conference

Here's What to Look for at the J.P. Morgan Healthcare Conference

The biggest annual event for biotech and pharma investors starts Monday with the kickoff of the J.P. Morgan Healthcare Conference in San Francisco.

What Biotech Investors Can Expect From the J.P. Morgan Health Care Conference 2017

What Biotech Investors Can Expect From the J.P. Morgan Health Care Conference 2017

Every January at 'JPM,' investors take the pulse of the biotech industry for the coming year.

Russell 2000 Paces Gains

I bought ProShares Ultra QQQ ETF and Tarena International and sold two-thirds of my Ross Stores.

Celgene Corporation To Announce Fourth Quarter And Full-Year 2016 Results On January 26, 2017

Celgene Corporation To Announce Fourth Quarter And Full-Year 2016 Results On January 26, 2017

Celgene Corporation (NASDAQ:CELG) will host a conference call and live audio webcast on Thursday, January 26, 2017 at 9 a.

17 Thoughts on Biotech Stocks to Kick Off 2017

17 Thoughts on Biotech Stocks to Kick Off 2017

Adam Feuerstein compiles a list of questions, thoughts, declarations, catalysts and observations about biotech stocks to help investors prepare for the year ahead.

Starbucks, Allergan, Amazon: Doug Kass' Views

Starbucks, Allergan, Amazon: Doug Kass' Views

Doug Kass shares his thoughts on how 2017 will be the year of 'the Dude.'

Doug Kass' Top Pick for 2017: Short QQQ

Doug Kass' Top Pick for 2017: Short QQQ

Kass' trade of the year for 2017 is to short the PowerShares QQQ Trust ETF.

My Top Pick for 2017: Short QQQ

My Top Pick for 2017: Short QQQ

Six reasons why the Nasdaq 100 ETF seems ready to pull back.

Allergan, Apple, Costco: Doug Kass' Views

Allergan, Apple, Costco: Doug Kass' Views

Doug Kass shares his thoughts on the post-fact investment world and delivers his verdict on Caterpillar.

'Mad Money' Lightning Round: Southwestern Energy, UnitedHealth, Celgene and More

'Mad Money' Lightning Round: Southwestern Energy, UnitedHealth, Celgene and More

Jim Cramer favors UnitedHealth over Cerner, and U.S. Concrete more than Cemex.

Jim Cramer's 'Mad Money' Recap: Don't Worry About a Little Market Detour

Jim Cramer's 'Mad Money' Recap: Don't Worry About a Little Market Detour

Get used to some down days, says Jim Cramer, but don't lose sight of the success for financial stocks.

What Adam Feuerstein Got Right and Wrong About Biotech Stocks in 2016

What Adam Feuerstein Got Right and Wrong About Biotech Stocks in 2016

TheStreet's biotech columnist offers his own report card on biotech stocks.

Oral OTEZLA®¿ (Apremilast) Receives Positive Nice Recommendation For Adults With Psoriatic Arthritis

Oral OTEZLA®¿ (Apremilast) Receives Positive Nice Recommendation For Adults With Psoriatic Arthritis

Celgene announced today that the National Institute for Health and Care Excellence (NICE) has issued a final appraisal determination (FAD) recommending the use of OTEZLA (apremilast) for the treatment of adult patients with...

Oral PDE-4 Inhibitor, OTEZLA®, Approved For The Treatment Of Plaque Psoriasis And Psoriatic Arthritis In Japan

Oral PDE-4 Inhibitor, OTEZLA®, Approved For The Treatment Of Plaque Psoriasis And Psoriatic Arthritis In Japan

Celgene Corporation (NASDAQ:CELG) today announced that OTEZLA ® (apremilast), Celgene's oral selective inhibitor of phosphodiesterase 4 (PDE4), has been granted full marketing authorization by Japan's Ministry of...

Apple, Alphabet, Starbucks: Doug Kass' Views

Apple, Alphabet, Starbucks: Doug Kass' Views

Doug Kass shares his thoughts on divergences in the market's armor and observes that real tech regulation is complicated.

WBA, FB, GOOGL: Jim Cramer's Views

WBA, FB, GOOGL: Jim Cramer's Views

Cramer shares his views on Diamondback's Permian buy and wonders if airlines will soon be playing leapfrog.

Allergan, Apple, Oakland Capital: Doug Kass' Views

Allergan, Apple, Oakland Capital: Doug Kass' Views

Doug Kass shares his thoughts on China and life insurers.

Agios Shelves Rare Anemia Disorder Drug Due to Liver Toxicity, Switches to Backup

Agios Shelves Rare Anemia Disorder Drug Due to Liver Toxicity, Switches to Backup

Agios owns the full rights to both drugs in the PKD development program, which makes them particularly important to the company.